NEW YORK, March 26, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced that a poster presentation highlighting pre-clinical data of the potential use of the Company’s guanylate cyclase-C agonists to treat ulcerative colitis and to delay its progression into colon cancer will be presented at the upcoming AACR Annual Meeting 2012 to be held from March 31, 2012 to April 4, 2012 at the McCormick Place Convention Center in Chicago, IL. The reported work was jointly accomplished by scientists from Synergy and from Fox Chase Cancer Center, Philadelphia and is funded through a grant from the National Cancer Institute to Dr. Kunwar Shailubhai, Chief Scientific Officer of Synergy Pharmaceuticals.
